Rituximab ITP Aiha denied for missing prior authorization by Humana?

Humana's specific coverage criteria for rituximab itp aiha are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Rituximab (ITP/AIHA)

Rituximab is a high-cost specialty biologic, and Humana requires prior authorization (PA) before it will cover an infusion claim. A PA denial — or a claim denial for rituximab administered without an approved PA — typically occurs because the PA was never submitted, was submitted with insufficient clinical information, or was denied because the submitted documentation did not satisfy all of Humana's coverage criteria at the time of review. In each case, the appropriate path is an appeal that provides complete, organized clinical documentation.

## Why This Denial Is Appealable

PA denials are not final medical judgments. They reflect the information available at the time of the initial review. If additional clinical detail — a more complete treatment history, a stronger prescriber letter, or documentation of disease severity that was missing from the original submission — can now be provided, the denial is likely to be overturned. If your prescriber attempted to obtain PA and received incorrect guidance from Humana, a plan-administration error argument may also be available.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 and ACA §2719, you have the right to a full internal appeal. File within the timeframe shown on your denial notice. Humana must review the complete clinical record — not just the original PA submission — and provide a written decision.
• Peer-to-peer review: Your hematologist may request a direct clinical discussion with Humana's reviewing physician before or alongside the formal appeal. This step alone resolves many PA denials for specialty biologics.
• External review: If the internal appeal is denied, federal rules generally allow approximately four months to request IRO external review. An independent clinician with hematology expertise will assess whether the denial is consistent with accepted medical practice.
• Expedited PA and appeal: Request expedited processing simultaneously if treatment delay poses serious health risk — relevant for active ITP with bleeding or symptomatic AIHA.

## Documentation to Gather

• Hematologist medical-necessity letter: Detailed, specific to this patient — covering the diagnosis, disease severity, prior treatments and outcomes, and clinical rationale for rituximab.
• Diagnosis and severity documentation: CBC trends, transfusion records, hemolysis markers, bone marrow findings if available, and recent clinical notes.
• Prior-treatment history: A complete, dated list of all therapies previously tried with documented outcomes — organized to match Humana's step-therapy or prior-failure requirements.
• Humana's coverage policy: Download the current published policy for rituximab and use it as a line-by-line checklist for your submission.

## Criteria-Mapping Structure

For each criterion in Humana's PA policy, create a table row: left column states the criterion exactly as written; right column cites the specific chart entry, date, and finding that satisfies it. Where a criterion requires documented failure of a prior therapy, attach the relevant prescription record or clinical note. A criterion-mapped submission eliminates the reviewer's ability to deny on grounds of missing information.